https://inside.ouhsc.edu/ Parent Page: News id: 14023 Active Page: detailsid:14024
Stephenson Cancer Center Urologic Oncologist Elected To National Leadership Role
Michael Cookson, M.D., MMHC, FACS is chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Stephenson Cancer Center Urologic Oncologist Elected To National Leadership Role


Published: Wednesday, December 4, 2019

Urologic oncologist Michael Cookson, M.D., MMHC, FACS, was recently elected president of the Society of Urologic Oncology.

Cookson is chairman of the Department of Urology at the University of Oklahoma College of Medicine and holds the Donald D. Albers Endowed Chair in urology. He sees urologic cancer patients at Stephenson Cancer Center at OU Medicine. He was installed in his new role at the Society’s annual meeting December 3, in Washington, D.C., and will serve a one-year term.

“I am indeed honored to lead one of the most significant international organizations that advocates for urologic cancer care,” said Cookson. “SUO strives to bring together distinguished experts whose work is entirely or primarily focused on malignant diseases of the urinary tract that include prostate and bladder cancer. In this way, we harness our experience and expertise to conquer urologic cancers.”

As an organization, SUO offers members a forum for discussion, development and implementation of ideas to improve care for patients with malignant genitourinary diseases. Key objectives are to stimulate research and teaching in urologic oncology, disseminate principles of urologic oncology to the medical profession at large and to standardize fellowship training in urologic oncology.

In addition, Cookson said SUO is spearheading efforts with the American Board of Urology to develop a new Focus Practice Designation in Urologic Oncology for those physicians immersed in the care of urologic cancer patients. “The goal of this initiative will be to allow patients to identify doctors who are experts in the field with the ultimate goal of improving patient outcomes for those diagnosed with prostate and urologic cancers.”